期刊
CHEMMEDCHEM
卷 15, 期 11, 页码 933-948出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202000131
关键词
cardiotoxicity; doxorubicin; drug discovery; multidrug resistance; topoisomerases
资金
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/10837-0, 2016/211946]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]
Anthracyclines are ranked among the most effective chemotherapeutics against cancer. They are glycoside drugs comprising the amino sugar daunosamine linked to a hydroxy anthraquinone aglycone, and act by DNA intercalation, oxidative stress generation and topoisomerase II poisoning. Regardless of their therapeutic value, multidrug resistance and severe cardiotoxicity are important limitations of anthracycline treatment that have prompted the discovery of novel analogues. This review covers the most clinically relevant anthracyclines and their development over decades, since the first discovered natural prototypes to recent semisynthetic and synthetic derivatives. These include registered drugs, drug candidates undergoing clinical trials, and compounds under pre-clinical investigation. The impact of the structural modifications on antitumour activity, toxicity and resistance profile is addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据